Tempe, AZ, April 28, 2015 – Statistics & Data Corporation (SDC), a specialized biostatistics and clinical data management Contract Research Organization (CRO), and PRC Clinical, a Clinical Trial Management Expert CRO based in the Silicon Valley, are pleased to announce they have formalized their partnership by signing a Strategic Alliance Agreement.
SDC and PRC Clinical have partnered to provide full-service offerings on various clinical trials over the past 4 years. During this time, the companies have built a collaborative partnership that transcends a typical CRO-vendor relationship. “We have had a great relationship in place with PRC Clinical since 2011. Now that we have successfully supported multiple clinical trials for our shared clients, our management teams believe that this Strategic Alliance Agreement is the final step in formalizing our partnered approach,” said Jim Townsend, Vice President of Business Development at SDC.
“The PRC Clinical team is excited to formalize our solid and long-standing partnership with SDC” states Curtis Head, CEO at PRC Clinical. “We will further leverage our combined expertise and abilities on projects in the United States and beyond”. Earlier this year, PRC Clinical and SDC travelled to Israel to exhibit at the inaugural Outsourcing in Clinical Trials Conference in Tel-Aviv, and aim to support Israeli sponsors targeting to the US market.
Highlights of SDC and PRC Clinical’s Strategic Alliance include:
Simplified outsourcing process for full-service projects
No vendor management hassle for clients – one seamless, expert project team under one contract
Efficient processes and familiar study teams following years of collaboration
Shared culture of providing personalized services and superior customer service to clients
With the relationship formalized and the Strategic Alliance Agreement in place, SDC and PRC Clinical plan to continue supporting clinical trials as a seamless full-service CRO solution.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.